Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131378 · ClinicalTrials.gov registry record · NA
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 142
- Enrollment target
NCT00131378: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00131378 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 142 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131378, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body composition will be measured.
Interventions
- DRUG Nutropin AQ growth hormone
- DRUG Placebo Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2004-11 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131378
The ClinicalTrials.gov registry entry for NCT00131378 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nutropin AQ growth hormone is the first listed.
NCT00131378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131378 about?
NCT00131378 is a clinical study titled "Growth Hormone, Cardiovascular Risk, and Visceral Adiposity". This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be administered and effects on cardiovascular risk, insulin resistance and body compo...
What is the current status of trial NCT00131378?
This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2004-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00131378?
The interventions under investigation include: Nutropin AQ growth hormone (DRUG), Placebo Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT00131378?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.